Clinical-Lab-Data-Analysis

Demographics

Table 1: Age

Category	Drug Group Mean	Drug Group Std Dev	Control Group Mean	Control Group Std Dev
Recipient	41.94	10.62	36.70	11.42
Donor	49.02	11.41	47.67	11.43

Table 2: Relationship of Recipient with Donor

Category	Drug Group Records	Control Group Records
Related	3	6
Spousal	5	-
Unrelated	2	4
Total	10	10

Table 3: Gender Analysis

Category	Drug Group N	Control Group N
Recipient	10	1 (female), 8 (male)
Donor	10 (female)	6 (female), 3 (male)

Insights:

A. Age:

1. Drug Group: Recipients have an average age of 41.94 years (Std Dev: 10.62), while donors average 49.02 years (Std Dev: 11.41).
2. Control Group: Recipients are younger, averaging 36.70 years (Std Dev: 11.42), with donors at 47.67 years (Std Dev: 11.43).

B. Relationship with Donor:

1. Drug Group: Most donors are spousal (5), followed by related (3), and unrelated (2).
2. Control Group: More recipients are related to donors (6) compared to unrelated (4).

C. Gender Analysis:

1. Drug Group: All recipients are male (10) and all donors are female (10).
2. Control Group: Recipients are mostly male (8), with one female, while donors are predominantly female (6), with three males.

Lab Data

Table 1: Analysis of Serum Creatinine on Different Days

Day	Drug Group N	Drug Group Mean	Drug Group Std	Drug Group Range	Control Group N	Control Group Mean	Control Group Std	Control Group Range
day3	10	1.87	1.54	5.30	9	1.83	0.59	1.90
day7	10	1.53	0.73	2.60	9	1.64	0.41	1.30
day15	8	1.58	0.52	1.80	9	1.68	0.62	2.00
day30	7	1.62	0.18	0.50	8	1.46	0.39	1.10
day90	3	1.60	0.10	0.20	4	1.43	0.15	0.30
day180	2	1.55	0.35	0.50	2	1.50	0.14	0.20
day360	2	1.50	0.14	0.20	0	.	.	.
day720	1	1.50	.	0.00	0	.	.	.

Table 2: Analysis of HB on Different Days

Day	Drug Group N	Drug Group Mean	Drug Group Std	Drug Group Range	Control Group N	Control Group Mean	Control Group Std	Control Group Range
day0	8	9.03	1.68	5.70	9	8.39	1.80	5.40
day3	8	8.76	3.41	10.50	9	8.68	2.17	5.80
day7	8	9.23	2.24	7.50	9	8.83	2.60	8.20
day14	8	10.14	1.63	5.80	8	10.33	1.66	4.50
day30	7	10.19	1.45	4.10	8	12.23	1.29	3.40
day90	3	12.57	0.29	0.50	4	11.85	1.42	3.40
day180	2	12.55	1.34	1.90	2	14.10	0.28	0.40
day360	2	13.10	0.99	1.40	0	.	.	.
day720	0	.	.	.	0	.	.	.

Table 3: Analysis of Platelets on Different Days

Day	Drug Group N	Drug Group Mean	Drug Group Std	Drug Group Range	Control Group N	Control Group Mean	Control Group Std	Control Group Range
day0	4	221.50	62.96	132.00	9	225.7	54.04	166.8
day3	4	166.75	36.37	84.00	9	197.9	34.58	157.7
day7	6	227.67	134.36	397.00	9	9.23	2.24	7.50
day14	3	318.33	112.45	204.00	8	10.14	1.63	5.80
day30	2	168.00	32.53	46.00	7	10.19	1.45	4.10
day90	1	190.00	.	0.00	3	12.57	0.29	0.50
day180	0	.	.	.	2	12.55	1.34	1.90
day360	2	226.00	155.56	220.00	2	13.10	0.99	1.40
day720	1	287.00	.	0.00	0	.	.	.

Table 4: Analysis of Urine Test

Day	Drug Group Records Observed	Control Group Records Observed
day0	0	0
day3	0	1
day7	0	1
day14	4	4
day30	7	5
day90	4	2
day180	2	2
day360	2	0
day720	0	0

Table 5: Analysis of CD3 on Different Days

Day	Drug Group N	Drug Group Mean	Drug Group Std	Drug Group Range	Control Group N	Control Group Mean	Control Group Std	Control Group Range
day0	5	837.00	509.54	1137.00	2	198.50	72.83	103.00
day3	7	42.29	55.94	122.00	1	298.00	.	0.00
day7	2	543.50	218.50	309.00	0	.	.	.
day14	0	.	.	.	1	570.00	.	0.00
day30	4	318.25	246.33	548.00	4	648.75	300.27	663.00
day90	1	236.00	.	0.00	5	943.80	644.86	1287.00
day180	1	523.00	.	0.00	1	780.00	.	0.00
day360	0	.	.	.	0	.	.	.
day720	1	1042.00	.	0.00	0	.	.	.

Table 6: Analysis of CD4 on Different Days

Day	Drug Group N	Drug Group Mean	Drug Group Std	Drug Group Range	Control Group N	Control Group Mean	Control Group Std	Control Group Range
day0	6	401.83	342.32	859.00	2	98.00	45.25	64.00
day3	7	11.14	23.03	63.00	1	124.00	.	0.00
day7	2	295.00	213.55	302.00	0	.	.	.
day14	0	.	.	.	1	157.00	.	0.00
day30	4	107.25	109.54	257.00	4	246.50	140.71	330.00
day90	1	176.00	.	0.00	5	463.40	437.96	890.00
day180	1	306.00	.	0.00	1	306.00	.	0.00
day360	0	.	.

Summary of lab data

1. Serum Creatinine Analysis Day 3: Drug group had a higher mean serum creatinine (1.87) than the control group (1.83). Day 7: Both groups show a reduction in mean serum creatinine, but the control group shows a more significant reduction.
2. Hemoglobin (HB) Analysis Day 14: Drug group's HB levels increased significantly from 9.23 to 10.14, while the control group's HB rose from 8.83 to 10.33. Day 180: Control group showed a greater increase (14.10) compared to the drug group (12.55).
3. Platelet Count Analysis Day 14: Drug group had a significantly higher mean platelet count (318.33) compared to the control group. Day 360: The drug group maintained higher platelet counts (226.00) than the control group.
4. CD3 and CD4 Counts CD3 Day 30: Control group showed higher mean CD3 levels (648.75) compared to the drug group (318.25). CD4 Day 30: Control group also showed higher CD4 levels (246.50) compared to the drug group (107.25).
5. Viral Infections Both groups reported two cases of viral infection.